Comparing short and standard radiation therapy for thyroid eye disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of a shortened regimen of external beam radiation therapy (ERT) for patients with moderate to severe thyroid eye disease, comparing it to the standard treatment protocol. Participants will be randomized into two groups: one receiving 10 sessions of ERT and the other receiving 5 sessions. The study aims to determine if the reduced treatment schedule can maintain efficacy while improving patient quality of life. Comprehensive assessments will be conducted to monitor symptoms, vision, and overall treatment response throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with active moderate to severe thyroid eye disease with a CAS \> 4 with/ without diplopia before starting IVMP
* Patient with poor response to 3 doses of IVMP (CAS drop \< 1) หรือ CAS score \> 3 after 3 doses of IVMP
* Patients with diplopia after 3 doses of IVMP
* Patients with Graves' Ophthalmopathy who have maintained euthyroidism
* Non-pregnant adults (aged 35 years or older)

Exclusion Criteria:

* Individuals with severe hypertension or diabetic retinopathy

Where it's running

• Faculty of Medicine Siriraj Hospital Mahidol University
  Bangkok Noi, Thailand Recruiting

Study contacts

• Principal investigator: Janjira Petsuksiri, M.D. — Mahidol University
• Study coordinator: Janjira Petsuksiri, M.D.
• Email: janjira.pet@mahidol.ac.th
• Phone: 66919966662

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Precise diagnosis and treatment system for thyroid-associated eye disease

  This project will test whether a deep-learning system using eye images and exams can automatically diagnose, stage, and help plan treatment for people with thyroid-associated ophthalmopathy.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07124572

• Combining Tocilizumab and Flupentixol-Melitracen for Thyroid Eye Disease Treatment

  This study is testing if combining two medications, Tocilizumab and Flupentixol-Melitracen, can help people with thyroid eye disease feel better and improve their eye symptoms.

  Recruiting Phase 4 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT06927375

• Multiparametric prediction models for moderate to severe thyroid-associated eye disease

  This project will try to build and test combined imaging and lab-marker models to predict outcomes in adults with moderate to severe thyroid-associated ophthalmopathy.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT06590220

• Evaluating linsitinib for thyroid eye disease

  This study is testing if a new drug called linsitinib can help people with moderate to severe thyroid eye disease who haven't improved with other treatments.

  Recruiting at 2 sites Phase 2/3 Sling Therapeutics, Inc. · Miami, Florida and 1 other locations · NCT06112340

• Evaluating doxycycline for treating Thyroid Associated Ophthalmopathy

  This study is testing if doxycycline can help people with Thyroid Associated Ophthalmopathy feel better and improve their eye symptoms.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT05112211

• Comparing Sirolimus and Corticosteroids for Thyroid Eye Disease

  This study tests whether Sirolimus can be a safer and more effective treatment for people with moderate-to-severe thyroid eye disease compared to traditional corticosteroids.

  Recruiting Phase 2 Haukeland University Hospital · Bergen, Hordaland · NCT04936854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.